domingo, 8 de septiembre de 2013

Prospective cost-effectiveness analysis of geno... [Eur J Cancer. 2013] - PubMed - NCBI

Prospective cost-effectiveness analysis of geno... [Eur J Cancer. 2013] - PubMed - NCBI
Eur J Cancer. 2013 Aug 27. pii: S0959-8049(13)00735-1. doi: 10.1016/j.ejca.2013.08.001. [Epub ahead of print]

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.


Netherlands Cancer Institute (NKI-AVL), Department of Psychosocial Research and Epidemiology, Amsterdam, The Netherlands.



The cost-effectiveness of the 70-gene signature (70-GS) (MammaPrint®) has earlier been estimated using retrospective validation data. Based on the prospective 5-year survival data of the microarRAy-prognoSTics-in-breast-cancER (RASTER) study, the aim here was to evaluate the cost-effectiveness reflecting the actual use in clinical practice, including reality-based compliance rates.


Costs and outcomes (quality-adjusted-life-years (QALYs)) were calculated in node-negative (N-) patients included in the RASTER study (n=427). Sensitivity and specificity of the 70-gene and Adjuvant! Online (AO) were based on 5-year distant-disease-free survival (DDFS). Subgroup analyses were performed for two groups for whom benefit of the 70-gene had earlier been reported: (1) ductal, oestrogen receptor-positive (ER+), tumour diameter 10-30mm, grade II, age 40-70; (2) ductal, oestrogen receptor-positive, tumour diameter 5-30mm, grade II/III and age 40-70.


Based on 5-year survival data, the cost-effectiveness of the 70-gene signature versus AO was prospectively confirmed. The total health care costs per patient were €26,786 for the 70-gene and €29,187 for AO. The quality adjusted life years yielded 12.49 and 11.88, respectively. The subgroups retrieved slightly higher life gains and higher costs, but all resulted finally in a favourable position for the 70-gene signature.


The use of the 70-gene signature, as judged appropriate by doctors and patients and supported by a low risk 70-gene signature as an oncological safe choice, was also found to be cost-effective.
Copyright © 2013. Published by Elsevier Ltd.


Adjuvant systemic treatment, Breast cancer, Gene expression profiling, Real world cost-effectiveness
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario